LEXINGTON, Mass.–(BUSINESS WIRE)–January 12, 2016–

Second paragraph of release dated January 11th, 2016, should read: Kevin Hrusovsky, Executive Chairman and CEO, will be presenting an overview of the company, its strategic priorities and vision for transforming medicine on Tuesday, January 12, 2016 at 2:30 p.m. PT (5:30 p.m. ET)  (instead of 11:30 a.m. ET).

The corrected release reads:

QUANTERIX TO PRESENT AT THE 34TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Quanterix Corporation, a leader in high definition technology for life sciences and diagnostics, today announced that it will be presenting at the 34th Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California.

Kevin Hrusovsky, Executive Chairman and CEO, will be presenting an overview of the company, its strategic priorities and vision for transforming medicine on Tuesday, January 12, 2016 at 2:30 p.m. PT (5:30 p.m. ET).

With applications across a wide spectrum of therapeutic areas, including cardiology, neurology, infectious disease, oncology and inflammatory disease, Quanterix’ ultra-sensitive diagnostic platform, Simoa, is capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Company’s annual growth has exceeded 100 percent quarter over quarter over the past 18 months and it is raising capital to further accelerate the vast potential for its technology. The Company has received significant recognition, including several prominent industry award wins, such as the GE – NFL Head Health Challenge, and was featured in 51 distinguished scientific publications, with a strong pipeline of new research to come. Hrusovsky will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

“Our single molecule detection technology has demonstrated its game-changing capabilities for life sciences and diagnostics, and our company is in an increasingly strong position to create compelling value,” said Hrusovsky. “We are excited for the opportunity to provide the investment community with an update on our business, including our robust pipeline, product development plans, strategy and vision for the future.”

A live audio webcast of the presentation will be available through the Events/News page of the company’s website, which can be found here: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink.php?p=20397.

To learn more about Quanterix, please visit: http://www.quanterix.com.

About Quanterix
Quanterix is a developer of ground-breaking tools in life sciences and high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.

PAN Communications
Nikki Festa & Caitlyn Keating, 617-502-4300
quanterix@pancomm.com